Cost-Effectiveness Analysis of Bevacizumab- Paclitaxel-Carboplatin (PC) Versus PC in First-Line Therapy of Advanced Non-Small Cell Lung Cancer from Patients' Perspective in Vietnam. | Value Health;17(7): A634-5, 2014 Nov. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Cost-Effectiveness Analysis of Bevacizumab- Paclitaxel-Carboplatin (PC) Versus PC in First-Line Therapy of Advanced Non-Small Cell Lung Cancer from Patients' Perspective in Vietnam.

Tran, T T H; Nguyen, T T T.

Affiliation

Tran TT; University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam.
Nguyen TT; University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam.

Value Health ; 17(7): A634-5, 2014 Nov.

Article in En | MEDLINE | ID: mdl-27202258

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2014 Document type: Article Affiliation country: Vietnam

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2014 Document type: Article Affiliation country: Vietnam